German health minister Jens Spahn calls for faster adoption of biosimilars

pharmafile | November 14, 2018 | News story | Research and Development AbbVie, Germany, biosimilars, jens Spahn 

Germany’s health minister Jens Spahn has called for faster uptake of biosimilars in an effort to cut the cost of healthcare in Germany.

“Where there is a more affordable alternative at the same quality, we have to use it. Otherwise we won’t be able to sustain the high quality of pharmaceutical supply in Germany,” Spahn said.

Spahn, who has been pointed to as a potential successor to Angela Merkel, called for the faster adoption of the biological copies, after it was revealed that biosimilars would have saved the healthcare system €279 million last year.

The call has coincided with the entrance into the market of biosimilar versions of AbbVie’s Humira, which brought in $18 billion in sales last year.

Louis Goss

Related Content


Samsung Bioepis & Biogen receive positive CHMP opinion for ranibizumab biosimilar

Samsung Bioepis and Biogen have announced that the EMA’s Committee for Medicinal Products for Human …

Biosimilars and Brexit: What’s in store for UK’s biosimilar market?

It’s been 15 years since the first biosimilar entered the market, and the impact of …

NHS building

Abbvie psoriatic arthritis drug approved for use in Scotland

Abbvie’s RINVOQ (upadacitinib) drug, for the treatment of active psoriatic arthritis (PsA) in adults, has …

Latest content